Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma is a new market research publication announced by Reportstack. Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics...
More...




